ABSTRACT
INTRODUCTION

53
Sepsis is a generalized systemic inflammatory condition elicited by pro-inflammatory 54 cytokines released by host immune cell in response to exotoxin or endotoxins secreted by 55 bacteria. Overproduction of these cytokines is associated with multiple organ failure which is 56 the major cause of death in critically ill and elderly patients. Despite recent advances in our 57 understanding of the pathophysiological mechanism of sepsis and improved antimicrobial 58 therapy, the mortality rate from sepsis remains frustratingly high. Unfortunately many of the 59 therapeutic options proposed over the years for the management of sepsis and its 60 complication have either failed to meet their initial expectations or remained unproved.
61
Strategies are currently being developed to minimize the inflammatory response associated 62 with sepsis through immunotherapy (1).
63
Several reports have provided evidence of immunomodulatory activity of macrolide length of hospital stay and mortality rates (7, 8) .
69
Azithromycin, belonging to macrolide antibacterial class has been earlier reported to provide 70 survival benefit in the lipopolysaccharide (LPS) induced sepsis model (9). In the present 
RESULTS
79
Survival in Sepsis model
80
In the LPS induced sepsis model, azithromycin administered 1 h prior to lethal dose of LPS 81 showed dose dependent improvement in 24 h survival. Azithromycin at 100 mg/kg, i.p. 82 provided survival in 75 % of mice as compared to 12.5% in LPS group, which was 83 statistically significant (p<0.05) (Figure 1 ). Survival benefit of azithromycin was further 84 determined in CLP sepsis, a model having best correlation to human sepsis. In this model, 85 azithromycin at 100 mg/kg dose provided protection in 37.5 % of mice in contrast to 75% in 86 LPS treated mice, indicating that azithromycin might have little or no effect on the spread of µM/min/mL at 50 mg/kg and 629.08 ± 42.3 µM/min/mL at 100 mg/kg), however the effect 125 was significant (p<0.05) only at 100 mg/kg ( Figure 5A and 5B).
126
In the CLP challenged mice, plasma GSH was significantly reduced and plasma MPO was saline to obtain 20% homogenate from which 100 µl was used for bacterial count and the 289 remaining was centrifuged at 15000 rpm for 10 minutes at 4 ºC for cytokine measurements.
290
Lungs from remaining mice were homogenized with 50 mM potassium phosphate buffer (pH 291 6.0) containing 0.5 % hexadecyltrimethylammonium bromide, sonicated and centrifuged to 292 obtain supernatant for MPO estimation.
293
Measurements
294
Body temperature and blood glucose 295 Rectal temperature was measured 18 h after LPS and CLP challenge using digital TS glucometer.
298
Estimation of Total WBC count
299
Blood samples collected in EDTA were analyzed on automatic blood cell counter (Sysmex 300 haematology analyzer) for determining the total white blood cells.
301
Estimation of Plasma cytokine levels
302
Tumor necrosis factor-α (TNF-α), Interleukin 6 (IL-6), and IL-1β were estimated using We thank Wockhardt for granting permission to perform the studies. showed significantly lower WBC, blood glucose and body temperature compared to normal 507 control group. In LPS treated mice, azithromycin exhibited no effect on the WBC count; 
